Literature DB >> 98860

Results of reoperation for hyperparathyroidism, with evaluation of preoperative localization studies.

A J Edis, P F Sheedy, O H Beahrs, J A van Heerden.   

Abstract

During the past 3 years (June, 1974, to July, 1977), 51 patients underwent reoperation for persistent or recurrent hyperparathyroidism at the Mayo Clinica. The overall success rate for cervical reoperation was 72% and for mediastinal reoperation, was 64%. Arteriography alone provided accurate preoperative localization of missing parathyroid tumors in 11 of 17 patients at a cost per patient benefited of approximately $1,700. Selective thyroid venous sampling with parathormone assay alone correctly lateralized hyperfunctioning glands in only four of nine patients at a cost per patient benefited of approximately $1,900. When used in combination, these studies provided correct localization or lateralization of parathyroid tumors in five of seven patients at a cost per patient benefited of approximately $2,000. Three patients experienced significant neurological complications as a result of thyrocervical arteriography. There were no complications due to venous sampling. In patients who has undergone a less than thorough initial explorations due to venous sampling. In patients who had undergone a less than thorough initial exploration of the neck, the success rate for reoperation was not enhanced by obtaining preoperative tumor localization studies. However, in those patients who had had a thorough and systematic exploration of the neck at their first operations, the success rate for reoperation was almost doubled when preoperative arteriography or venous sampling (or both) was employed.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 98860

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  32 in total

1.  Causes of failed primary exploration and technical aspects of re-operation in primary hyperparathyroidism.

Authors:  G Akerström; C Rudberg; L Grimelius; H Johansson; B Lundström; J Rastad
Journal:  World J Surg       Date:  1992 Jul-Aug       Impact factor: 3.352

2.  Parathyroid localization--how and when?

Authors:  A J Coakley
Journal:  Eur J Nucl Med       Date:  1991

3.  Undescended parathyroid adenomas as cause of persistent hyperparathyroidism.

Authors:  Paula Rioja; Germán Mateu; Leyre Lorente-Poch; Juan J Sancho; Antonio Sitges-Serra
Journal:  Gland Surg       Date:  2015-08

4.  Unexpected results using rapid intraoperative parathyroid hormone monitoring during parathyroidectomy for primary hyperparathyroidism.

Authors:  Ignazio Emmolo; Herbert Dal Corso; Giorgio Borretta; Gianluca Visconti; Alessandro Piovesan; Flora Cesario; Felice Borghi
Journal:  World J Surg       Date:  2005-06       Impact factor: 3.352

5.  Partial median sternotomy: an attractive approach to mediastinal parathyroid disease.

Authors:  Jason S Gold; Patricia I Donovan; Robert Udelsman
Journal:  World J Surg       Date:  2006-07       Impact factor: 3.352

6.  Management of patients with persistent or recurrent primary hyperparathyroidism.

Authors:  S E Carty; J A Norton
Journal:  World J Surg       Date:  1991 Nov-Dec       Impact factor: 3.352

7.  Reoperation for primary hyperparathyroidism: tips and tricks.

Authors:  Jean-François Henry
Journal:  Langenbecks Arch Surg       Date:  2010-02       Impact factor: 3.445

8.  Prospective comparison of radionuclide, ultrasound, and computed tomography in the preoperative localization of parathyroid glands.

Authors:  H L Carmalt; D J Gillett; J Chu; R A Evans; S Kos
Journal:  World J Surg       Date:  1988-12       Impact factor: 3.352

9.  Reoperation for primary hyperparathyroidism.

Authors:  W C McGarity; A L Goldman
Journal:  Ann Surg       Date:  1981-08       Impact factor: 12.969

10.  The problems encountered in the surgical management of primary hyperparathyroidism.

Authors:  S Kobayashi; A Sugenoya; Y Kasuga; H Masuda; M Fujimori; M Komatsu; S Takahashi; T Shimizu; S Yokoyama; F Iida
Journal:  Jpn J Surg       Date:  1991-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.